000			01269 a2200337 4500
005			20250514004237.0
264		0	_c20010906
008			200109s 0 0 fre d
022			_a0750-7658
024	7		_a10.1016/s0750-7658(01)00438-5 _2doi
040			_aNLM _beng _cNLM
100	1		_aSamama, C M
245	0	0	_a[Bounderies of the authorization to market and the therapeutic impass]. _h[electronic resource]
260			_bAnnales francaises d'anesthesie et de reanimation _cJun 2001
300			_a507-8 p. _bdigital
500			_aPublication Type: Editorial
650	0	4	_aAnticoagulants _xadverse effects
650	0	4	_aChondroitin Sulfates _xadverse effects
650	0	4	_aDermatan Sulfate _xadverse effects
650	0	4	_aDrug Approval _xlegislation & jurisprudence
650	0	4	_aDrug Combinations
650	0	4	_aFrance
650	0	4	_aHeparin _xadverse effects
650	0	4	_aHeparitin Sulfate _xadverse effects
650	0	4	_aHirudin Therapy
650	0	4	_aHirudins _xadverse effects
650	0	4	_aHumans
650	0	4	_aRecombinant Proteins _xadverse effects
773	0		_tAnnales francaises d'anesthesie et de reanimation _gvol. 20 _gno. 6 _gp. 507-8
856	4	0	_uhttps://doi.org/10.1016/s0750-7658(01)00438-5 _zAvailable from publisher's website
999			_c11399011 _d11399011